Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Victoria detects H5N1 avian influenza strain

It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Content from other channels on our network

SPC Global expands its Aussie-made footprint across North Asia

Food fraud study in the UK estimates costs to economy

Australia and Vietnam trade talks progress

foodpro wrap-up: the event welcomed over 10,000 visitors

interpack China to partner with AIP

From compliance to circularity: three ways pharma manufacturers can rethink resource management

Tomago Aluminium smelter gets green investment

Stantec acquires Sydney-based consultancy

Researchers recover silver from end-of-life solar panels

Soft Low-E coated photovoltaic glass reduces energy demand

$100K fine follows tower crane incident that caused hospital roof collapse

Nexon partners with Dementia Australia to tackle dementia stigma in the workplace

"Migrant worker exploitation" sees NSW aged care provider repay nearly $120K

A Day in the Life of a birth suite ANUM

Professor Andrea Driscoll MACN wins 2026 Nursing Trailblazers Award